



ORIGINAL ARTICLE

CRUSADE: Is it still a good score to predict bleeding in acute coronary syndrome?☆



Dina Bento^{a,*}, Nuno Marques^{a,b}, Pedro Azevedo^a, João Guedes^a, João Bispo^a, Daniela Silva^a, José Amado^a, Walter Santos^a, Jorge Mimoso^a, Ilídio de Jesus^a

^a Serviço de Cardiologia, Centro Hospitalar Universitário do Algarve, Faro, Portugal

^b Algarve Biomedical Center, Faro, Portugal

Received 12 October 2017; accepted 1 February 2018

Available online 30 November 2018

KEYWORDS

Major bleeding;
Acute coronary syndrome;
CRUSADE bleeding score;
In-hospital prognosis

Abstract

Introduction: Major bleeding is a serious complication of acute coronary syndrome (ACS) and is associated with a worse prognosis. The CRUSADE bleeding score is used to stratify the risk of major bleeding in ACS.

Objective: To assess the predictive ability of the CRUSADE score in a contemporary ACS population.

Methods: In a single-center retrospective study of 2818 patients admitted with ACS, the CRUSADE score was calculated for each patient and its discrimination and goodness of fit were assessed by the area under the receiver operating characteristic curve (AUC) and by the Hosmer-Lemeshow test, respectively. Predictors of in-hospital major bleeding (IHMB) were determined.

Results: The IHMB rate was 1.8%, significantly lower than predicted by the CRUSADE score (7.1%, $p < 0.001$). The incidence of IHMB was 0.5% in the very low risk category (rate predicted by the score 3.1%), 1.5% in the low risk category (5.5%), 1.6% in the moderate risk category (8.6%), 5.5% in the high risk category (11.9%), and 4.4% in the very high risk category (19.5%). The predictive ability of the CRUSADE score for IHMB was only moderate (AUC 0.73).

The in-hospital mortality rate was 4.0%. Advanced age ($p = 0.027$), femoral vascular access ($p = 0.004$), higher heart rate ($p = 0.047$) and ticagrelor use ($p = 0.027$) were independent predictors of IHMB.

Conclusions: The CRUSADE score, although presenting some discriminatory power, significantly overestimated the IHMB rate, especially in patients at higher risk. These results question whether the CRUSADE score should continue to be used in the stratification of ACS.

© 2018 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

☆ Please cite this article as: Bento D, Marques N, Azevedo P, et al. Score CRUSADE – Será ainda um bom score para prever a hemorragia na síndrome coronária aguda? Rev Port Cardiol. 2018;37:889–897.

* Corresponding author.

E-mail address: dinabento@gmail.com (D. Bento).

PALAVRAS-CHAVE

Score CRUSADE;
Síndrome coronária
aguda;
Hemorragia *major*;
Prognóstico
intra-hospitalar

Score CRUSADE – Será ainda um bom score para prever a hemorragia na síndrome coronária aguda?**Resumo**

Introdução: A hemorragia *major* (HM) é uma complicação grave da síndrome coronária aguda (SCA) e está associada a pior prognóstico. O score CRUSADE permite estratificar o risco de HM na SCA.

Objetivo: Avaliar a capacidade preditiva do score CRUSADE numa população contemporânea de SCA.

Métodos: Estudo unicêntrico e retrospectivo com 2.818 doentes admitidos por SCA. O score CRUSADE foi calculado para cada doente, a sua discriminação e calibração foram avaliadas pela área abaixo da curva (AUC) *Receiver Operating Characteristic* e pelo teste Hosmer-Lemeshow, respetivamente. Foram determinados os preditores de HM intra-hospitalar (HMIH).

Resultados: A taxa de HMIH foi de 1.8%, valor significativamente inferior ao estimado pelo score CRUSADE (7,1%, $p < 0,001$). A incidência de HMIH nas diferentes categorias foi de 0,5% na de muito baixo risco (taxa estimada pelo score de 3,1%); 1,5% na de baixo (estimada de 5,5%); 1,6% na de moderado (estimada de 8,6%); 5,5% na de elevado (estimada de 11,9%) e 4,4% na de muito elevado (estimada de 19,5%). A capacidade preditora do score CRUSADE para HMIH foi apenas moderada (AUC 0,73). A taxa de mortalidade intra-hospitalar foi de 4,0%. A idade mais avançada ($p = 0,027$), o acesso vascular femoral ($p = 0,004$), a frequência cardíaca mais elevada ($p = 0,047$) e o ticagrelor ($p = 0,027$) foram preditores independentes de HMIH.

Conclusão: O score CRUSADE, apesar de apresentar algum poder discriminatório, sobrestimou de forma significativa a taxa de HMIH, principalmente nos doentes de maior risco. Esses resultados questionam se o score CRUSADE deverá continuar a ser usado na estratificação da SCA.

© 2018 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. Este é um artigo Open Access sob uma licença CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

List of abbreviations

ACS	acute coronary syndrome
AUC	area under the curve
CABG	coronary artery bypass grafting
CI	confidence interval
COPD	chronic obstructive pulmonary disease
GP	glycoprotein
IHMB	in-hospital major bleeding
LVEF	left ventricular ejection fraction
MI	myocardial infarction
OR	odds ratio
PCI	percutaneous coronary intervention

Introduction

Patients with acute coronary syndrome (ACS) are a heterogeneous population, with varying levels of risk for events, and so initial assessment has a crucial role in deciding the most appropriate therapeutic strategy.¹ Treatment of these patients includes antithrombotic therapy and invasive procedures, which carry an increased risk of bleeding,² the incidence of which ranges between 1% and 10%.³ This variability in the incidence of bleeding complications is due to

various factors, including differences in patient characteristics, concomitant treatment and definitions of bleeding.³ Nevertheless, whatever definition is used, multiple studies have shown that bleeding complications are associated with adverse events including death, non-fatal myocardial infarction (MI), stroke, and stent thrombosis.³⁻⁵

Assessment of the risk of bleeding includes a detailed history of bleeding symptoms, identification of predisposing comorbidities, laboratory data, and calculation of a bleeding risk score.⁶

The CRUSADE score⁷ was developed to assess bleeding risk based on a varied population of patients with non-ST-elevation ACS (NSTEMI-ACS), and was subsequently validated for ST-elevation myocardial infarction (STEMI).⁸ It is calculated from eight variables that include baseline characteristics, clinical variables and admission laboratory values.⁷ It is currently the most commonly used score to determine bleeding risk, due to its proven discriminatory power.^{6,9,10}

The main purpose of the CRUSADE score is to stratify bleeding risk in patients with ACS, in order to select appropriate therapeutic strategies that will reduce bleeding events and hence improve prognosis.⁹

The aim of this study is to analyze the applicability of the CRUSADE score in ACS patients, in light of the significant changes that have taken place over the last decade in the management and treatment of these patients.

Methods

Study design

This was a retrospective, descriptive, correlational study of patients admitted with a diagnosis of ACS to the cardiology department of Centro Hospitalar Universitário do Algarve between October 1, 2010 and August 31, 2014. The CRUSADE score was calculated for each patient and its ability to predict in-hospital major bleeding (IHMB) was assessed. Predictors of IHMB were determined.

Patient selection

A total of 2818 patients diagnosed with ACS in the previous 48 hours were included. MI was diagnosed in the presence of chest pain or anginal equivalent in the previous 48 hours together with ischemic electrocardiographic changes (ST-segment deviation or negative T waves) and elevation of troponin levels above the reference value. Unstable angina was defined as the presence of chest pain or anginal equivalent with or without with ischemic electrocardiographic changes in the absence of elevation of troponin levels above the reference value.

Patients with MI associated with revascularization procedures (types 4 and 5) or type 2 MI according to the ESC/ACCF/AHA/WHF universal definition of myocardial infarction¹¹ were excluded.

In the analysis of the predictive ability of the CRUSADE score, 203 of the 2818 patients (7.2%) were excluded due to inability to calculate the score.

Data collection

Data were collected on demographics (age and gender), relevant personal history (MI, heart failure, percutaneous coronary intervention [PCI], coronary artery bypass graft surgery, chronic obstructive pulmonary disease [COPD] and cancer), and cardiovascular risk factors (hypertension, diabetes, dyslipidemia and smoking status). Data were also analyzed on hospital stay, including clinical parameters at admission (systolic blood pressure, heart rate and hematocrit), coronary angiography (vascular access and PCI), left ventricular ejection fraction (LVEF), type of ACS (STEMI, non-ST-segment MI [NSTEMI], MI of undetermined location, or unstable angina), and medication (aspirin, clopidogrel, ticagrelor, enoxaparin, unfractionated heparin, warfarin, and glycoprotein [GP] IIb/IIIa inhibitors).

Creatinine clearance was estimated by the Cockcroft-Gault formula.¹²

Vascular disease was identified on the basis of a history of peripheral arterial disease and/or stroke.

In-hospital mortality was defined as death from any cause during hospitalization for ACS.

Study objectives

The study objectives were assessment of the predictive ability of the CRUSADE score for in-hospital major bleeding

(IHMB) and determination of independent predictors of IHMB.

IHMB was defined according to the GUSTO classification as intracerebral bleeding or bleeding resulting in hemodynamic compromise requiring treatment.¹³ The CRUSADE score was calculated from eight variables (baseline hematocrit, estimated creatinine clearance, baseline heart rate, baseline systolic blood pressure, gender, signs of heart failure on presentation, prior vascular disease, and diabetes). The five bleeding risk categories defined by the CRUSADE investigators were used: very low risk (score ≤ 20), low risk (21-30), moderate risk (31-40), high risk (41-50), and very high risk (> 50).

Statistical analysis

A descriptive analysis was performed to characterize the study sample. Continuous variables are presented as mean \pm standard deviation and categorical variables as number (percentage).

The predictive ability of the CRUSADE score in our population was tested using the area under the curve (AUC) on receiver operating characteristic analysis¹⁴ and the model's goodness of fit was assessed by the Hosmer-Lemeshow test,¹⁵ in which adequate goodness of fit is indicated by a non-significant p value.

Associations between categorical variables were analyzed using the chi-square test and continuous variables using the Student's t test.

Binary logistic regression analysis was used to determine predictors of IHMB. A p-value of < 0.05 was considered to indicate a 95% significance level. IBM SPSS Statistics (version 20.0) was used for the statistical analysis.

Results

Population characteristics

The baseline characteristics of the study population are presented in [Table 1](#).

A total of 2818 ACS patients were included, 73.9% male, mean age 66 ± 13 years. At admission, mean hematocrit was $41 \pm 5\%$, mean heart rate was 77 ± 18 bpm, mean systolic blood pressure was 139 ± 30 mmHg, mean creatinine clearance was 81 ± 37 ml/min, and 10.9% presented signs of heart failure.

The most frequent diagnosis at admission was NSTEMI (48.4%), followed by STEMI (44.4%). Coronary angiography was performed in 75.3% of patients (91.5% by radial access), and 58.3% underwent PCI.

With regard to antithrombotic therapy during hospitalization, 96.8% of the patients received aspirin, 73% clopidogrel, 2.8% ticagrelor and 47.9% fondaparinux.

During hospital stay, 113 (4.0%) patients died and 52 (1.8%) presented IHMB.

Discriminatory power of the CRUSADE score

The rate of IHMB predicted in the study population was 7.1%, while the observed rate was 1.8%, a statistically significant difference ($p < 0.001$) ([Table 2](#)).

Table 1 Baseline characteristics of the study population (n=2818).

<i>Demographic data</i>	
Age, years	66±13
Male gender	73.9
<i>Cardiovascular risk factors</i>	
Hypertension	67.7
Dyslipidemia	59.9
Smoking	31.5
Diabetes	28.6
<i>Personal history</i>	
Heart failure	5.8
Coronary angioplasty	17.8
CABG	5.6
MI	25.2
Vascular disease ^a	16.3
Bleeding	3.2
<i>Baseline clinical and laboratory data</i>	
Signs of heart failure	10.9
Heart rate, bpm	77±18
SBP, mmHg	139±30
Hematocrit	41±5
Creatinine clearance, ml/min ^b	81±37
<i>Type of ACS</i>	
STEMI	44.4
NSTEMI	48.4
MI of undetermined location	3.4
Unstable angina	3.7
<i>Coronary angiography</i>	
Radial access	75.3
Femoral access	91.5
PCI	8.5
58.3	
<i>Antithrombotic therapy</i>	
Aspirin	96.8
Clopidogrel	73.0
Ticagrelor	2.8
GP IIb/IIIa inhibitors	49.0
Fondaparinux	47.9
Enoxaparin	16.6
Warfarin	5.1
IHMB	1.8
<i>In-hospital mortality</i>	4.0

ACS: acute coronary syndrome; CABG: coronary artery bypass graft surgery; GP: glycoprotein; IHMB: in-hospital major bleeding; MI: myocardial infarction; NSTEMI: non-ST-elevation myocardial infarction; PCI: percutaneous coronary intervention; SBP: systolic blood pressure; STEMI: ST-elevation myocardial infarction. Data are presented as mean ± standard deviation or as percentage.

^a Defined as peripheral arterial disease or previous stroke.

^b Estimated by the Cockcroft-Gault formula.

Table 2 In-hospital major bleeding observed in the study population and predicted by the CRUSADE score.

	Observed, n (%)	Predicted by the CRUSADE score, %	p
IHMB	52 (1.8)	7.1	<0.001

IHMB: in-hospital major bleeding.

The incidence of IHMB in the different categories of the CRUSADE score was 0.5% in the very low risk category (rate predicted by the score 3.1%), 1.5% in the low risk category (5.5%), 1.6% in the moderate risk category (8.6%), 5.5% in the high risk category (11.9%), and 4.4% in the high risk category (19.5%) (Table 3).

The predictive ability of the CRUSADE score in the study population was moderate, with an AUC of 0.73 (Figure 1).

Predictors of in-hospital major bleeding

The occurrence of IHMB was associated with the following variables: advanced age ($p=0.01$), hypertension ($p=0.029$), angina ($p=0.01$), previous bleeding ($p<0.001$), COPD ($p=0.021$), cancer ($p<0.001$), higher baseline heart rate ($p<0.001$), lower hemoglobin ($p=0.005$), femoral access ($p<0.001$), and lower LVEF at discharge ($p<0.001$). IHMB was also associated with higher in-hospital mortality (15.4% vs. 3.8%; $p<0.001$) (Table 4).

When the above significant associations were included in multivariate analysis, advanced age ($p=0.027$), femoral access ($p=0.004$), higher heart rate ($p=0.047$) and medication with ticagrelor during hospital stay ($p=0.027$) were identified as independent predictors of IHMB (Table 5).

Discussion

In this contemporary population of patients with ACS, the CRUSADE score overestimated the risk of IHMB.

In-hospital major bleeding

The incidence of IHMB in the literature is 1-10%; this variability is due to various factors including differences in patient characteristics, concomitant therapy and definitions of bleeding.³

The rate of IHMB in our study was 1.8%. This is significantly lower than that predicted by the CRUSADE score (7.1%) ($p<0.001$). The CRUSADE score overestimated bleeding risk in all risk categories, with greater differences in higher risk categories (moderate, high and very high).

These findings may be explained by evidence that the rate of IHMB in patients with ACS has decreased over time, despite the use of more aggressive drug therapies and interventions. Fox et al. reported a significant fall in bleeding rates in patients with ACS between 2000 and 2007, from 2.6% to 1.8% ($p<0.001$).¹⁶ Factors contributing to this decrease include improvements in cardiac catheterization techniques, the introduction of smaller catheters, the use

Table 3 In-hospital major bleeding observed in the study population and predicted by the CRUSADE score according to CRUSADE risk categories.

Bleeding risk	n=2615	Observed IHMB, n (%)	IHMB predicted by the CRUSADE score, %
Very low (1-20)	931	5 (0.5)	3.1
Low (21-30)	681	10 (1.5)	5.5
Moderate (31-40)	509	8 (1.6)	8.6
High (41-50)	289	16 (5.5)	11.9
Very high (>50)	205	9 (4.4)	19.5

IHMB: in-hospital major bleeding.




Figure 1 Receiver operating characteristic curve of the CRUSADE score for predicting in-hospital major bleeding in our population.

of radial access, better selection of antithrombotic therapy and changes to thresholds for red blood cell transfusion.¹⁶

Patients with IHMB have a worse prognosis, with greater risk for in-hospital mortality.^{16,17} In a study by Spencer et al. of 40 087 patients with MI, IHMB was associated with greater mortality (21% vs. 6%, $p < 0.001$).¹⁷ IHMB was also associated with higher mortality in our study (15.4% vs. 3.8%, $p < 0.001$). Measures must be taken to reduce the negative impact of IHMB on prognosis in ACS. However, several risk factors for bleeding are also predictors of ischemic events, complicating the task of maximizing anti-ischemic effectiveness while minimizing bleeding risk.^{7,10}

Discriminatory power of the CRUSADE score

The ability of the CRUSADE score to predict IHMB in our population was acceptable, with an AUC of 0.73. However, this is hardly an optimal result. In a cohort of 4500 patients with ACS, Abu-Assi et al. assessed the performance of the CRUSADE score, finding a c-statistic of 0.80 for predicting major bleeding events,⁹ and similarly, Manzano-Fernández et al. calculated an AUC of 0.79 in a study of 1587 patients with ACS.¹ However, other studies have reported lower figures: the AUC was 0.70 in a study of 1976 patients with

ACS by Ariza-Solé et al.,¹⁸ while Amador et al. found an AUC of 0.61 in their population of 516 ACS patients.¹⁹ The CRUSADE score has been shown to have poor predictive ability, with AUC values below 0.70, in certain subgroups, including those aged over 75 years, those who have not undergone coronary angiography, and those not receiving anticoagulant therapy.^{9,20,21} Its performance was actually rather modest (AUC 0.68) in the population in which the score was developed.⁷

There is thus considerable variability in the discriminatory power of the CRUSADE score in ACS patients. This may be due to a range of factors that hinder assessment of bleeding risk, including age, comorbidities, antithrombotic therapy, choice of strategy (invasive or conservative), and site of vascular access for angiography. There is a need for a score that is suitable for current clinical practice and that can provide accurate, individualized and simple bleeding risk stratification in patients with ACS.

Predictors of in-hospital major bleeding

The independent predictors of IHMB identified in our study were advanced age, higher heart rate on admission, femoral access and medication with ticagrelor during hospital stay.

As pointed out above, patients with ACS are a heterogeneous population, which means that different predictors of major bleeding will be found in different patient populations. A study by Mehran et al. in 17 421 patients with ACS identified seven predictors of bleeding, including female gender, advanced age, elevated serum creatinine, white cell count, anemia and use of unfractionated heparin plus a GP IIb/IIIa inhibitor.²² Moscucci et al. determined female gender, advanced age, renal insufficiency and history of bleeding as independent predictors of bleeding among 24 045 ACS patients in the GRACE registry.²³ As well as age, female gender and renal insufficiency, Nikolsky et al. identified pre-existing anemia, administration of low molecular weight heparin within 48 hours pre-PCI, and use of intra-aortic balloon pump as predictors of major bleeding.²⁴ Although there are differences between these studies in the incidence and definition of bleeding, age, female gender and renal failure are frequently identified variables.^{2,22,23} In our study, ticagrelor use was a predictor of IHMB, although it should be borne in mind that only 2.8% of our population were taking the drug. In the PLATO trial, compared to clopidogrel, treatment with ticagrelor reduced vascular mortality, MI and stroke, but was associated with a higher rate of bleed-

Table 4 Variables associated with in-hospital major bleeding.

	No IHMB (n=2766)	IHMB (n=52)	p	OR (95% CI)
Age, years	66±13	74±11	0.01	3.65 (2.05-6.92) ^a
Hypertension	67.4	82.0	0.029	2.31 (1.12-4.76)
Angina	39.0	56.9	0.01	2.13 (1.22-3.72)
Previous bleeding	2.9	20.0	<0.001	7.99 (3.87-16.50)
COPD	4.8	11.8	0.021	2.58 (1.08-6.15)
Cancer	4.2	15.7	<0.001	4.15 (1.91-9.02)
Heart rate, bpm	76±18	88±27	<0.001	4.01 (3.15-8.03) ^b
Hemoglobin, g/dl	13.8±1.8	13.1±2.2	0.005	2.90 (1.06-5.85) ^c
Femoral access	8.0	35.1	<0.001	6.10 (3.39-10.97)
LVEF	57±13	49±12	<0.001	5.15 (3.01-8.57) ^d
Enoxaparin	16.3	32.7	0.002	2.49 (1.38-4.49)
Warfarin	5.0	11.5	0.034	2.48 (1.04-5.92)
Ticagrelor	2.7	9.1	0.028	3.81 (1.48-9.87)
Mortality	3.8	15.4	<0.001	4.61 (2.12-10.03)

CI: confidence interval; COPD: chronic obstructive pulmonary disease; IHMB: in-hospital major bleeding; LVEF: left ventricular ejection fraction; OR: unadjusted odds ratio. Data are presented as mean ± standard deviation or as percentage.

^a For each additional 5 years.

^b For each additional 5 bpm.

^c For each reduction of 0.5 g/dl.

^d For each reduction of 5%.

Table 5 Predictors of in-hospital major bleeding.

	p	OR (95% CI)
Age	0.027	4.89 (3.01-7.13)
Heart rate	0.047	3.95 (1.87-8.10)
Femoral access	0.004	8.29 (5.01-10.18)
Ticagrelor	0.027	4.92 (1.89-8.15)

CI: confidence interval; OR: adjusted odds ratio.

ing not related to coronary artery bypass graft surgery (4.5% vs. 3.8%; $p=0.03$).²⁵

Vascular access for coronary angiography

In our study, 91.5% of patients underwent angiography via radial access, a higher proportion than in other studies assessing the applicability of the CRUSADE score, which reported rates between 64% and 83.1%.^{1,9,18,26} In multivariate analysis, femoral access was an independent predictor of IHMB ($p=0.004$), which is in line with recent clinical evidence.^{27,28} However, when interpreting this result it should be borne in mind that femoral access was used in only 8.5% of patients.

Periprocedural major bleeding is a complication that can affect patients undergoing PCI, with an incidence of 1.7-3.5% in recent studies.²⁹⁻³¹ Multiple studies have shown that radial access is associated with lower rates of periprocedural bleeding than femoral access.³²⁻³⁵

The RIVAL trial reported a lower rate of major vascular complications for radial access in patients with ACS (1.4% vs. 3.7%; $p<0.0001$).³⁵ However, results for mortality were inconsistent, with lower mortality in patients with STEMI but not in those with non-ST-elevation

ACS (NSTEMI-ACS). In the MATRIX trial, radial access reduced bleeding complications and overall mortality in patients with ACS (STEMI and NSTEMI) compared to femoral access.²⁷ In the European guidelines the use of radial access is a class I recommendation, level of evidence A.¹⁰

The high rate of radial access in our study may have contributed to the low rate of IHMB in our population. The fact that access type is not included in its parameters constitutes a limitation of the CRUSADE score.

Fondaparinux

Regarding anticoagulation, fondaparinux was used in 47.9% of our population, considerably more than enoxaparin (16.6%).

In the OASIS-5 trial in patients with NSTEMI-ACS, fondaparinux significantly reduced major bleeding events compared to enoxaparin ($p<0.001$).³⁶ Fondaparinux is the parenteral anticoagulant recommended in the current guidelines for NSTEMI-ACS patients, due to its safety and efficacy profile.¹⁰ Despite this recommendation, rates of fondaparinux use in other series are lower than in ours (1.6-14%).^{1,9,37}

We believe that the use of this anticoagulant in our population may also have contributed to the low rate of IHMB.

Glycoprotein IIb/IIIa inhibitors and P2Y₁₂ receptor inhibitors

GP IIb/IIIa inhibitors were used in 49% of our population, a higher rate than in other series (5.7-40.2%).^{1,9,18,19,37} It should, however, be noted that in most cases this consisted only of the administration of a bolus of eptifibatid during

coronary angiography and that the drug was not infused after angioplasty, which may have contributed to our low rate of periprocedural bleeding complications.

There is evidence that in patients with NSTEMI-ACS undergoing PCI, GP IIb/IIIa inhibitors reduce ischemic events, mainly reinfarction, although they also increase bleeding.^{6,38}

Following the HORIZONS-AMI trial, which showed that anticoagulation with bivalirudin alone was superior to heparin plus GP IIb/IIIa inhibitors in patients undergoing primary PCI, with significantly reduced 30-day rates of major bleeding and mortality,³⁹ use of GP IIb/IIIa inhibitors declined. The current European guidelines recommend GP IIb/IIIa inhibitors only for bailout or in cases of thrombotic complications (class IIa recommendation, level of evidence C).^{10,40}

By contrast, the US guidelines⁶ state that in patients with NSTEMI-ACS and high-risk features not adequately pretreated with clopidogrel or ticagrelor, it is useful to administer a GP IIb/IIIa inhibitor (class I recommendation, level of evidence A), and in NSTEMI-ACS patients treated with unfractionated heparin and adequately pretreated with clopidogrel, it is reasonable to administer a GP IIb/IIIa inhibitor (class IIa recommendation, level of evidence B).

It should be noted that our patients preferably received a P2Y₁₂ receptor inhibitor during or after angioplasty, which may also have contributed to the low rate of major bleeding. Current guidelines recommend pretreatment with a P2Y₁₂ receptor inhibitor for patients with ACS.^{6,10,40} However, questions have been raised^{41,42} concerning pretreatment in NSTEMI-ACS, such as by the ACCOAST trial,⁴² which demonstrated that pretreatment with prasugrel did not reduce the rate of ischemic events, but did increase the rate of major bleeding.

Clinical implications

Antithrombotic therapy, which is an essential part of anti-ischemic therapy in ACS, also increases bleeding risk. Patients with ACS are a highly heterogeneous population and stratification of both ischemic and bleeding risk is needed in order to institute appropriate therapy with the desired efficacy while minimizing undesired effects.³¹ However, in the last ten years there have been significant changes in the management and treatment of ACS patients that may have altered the predictive value of risk scores.¹⁰ There is thus a need to develop tools to stratify bleeding risk that aim to promote strategies that reduce bleeding rates and thereby improve prognosis in these patients.⁹

Limitations

This was a single-center, retrospective, observational study, and was thus subject to the inherent biases of such studies. The low rate of bleeding events may have influenced the results, which should be validated in a larger patient cohort.

The use of different definitions of major bleeding is another limitation of our study. In the CRUSADE trial, major bleeding was defined as intracranial hemorrhage, documented retroperitoneal bleed, hematocrit drop $\geq 12\%$ (baseline to nadir), any red blood cell transfusion when

baseline hematocrit $\geq 28\%$, or any red blood cell transfusion when baseline hematocrit $< 28\%$ with witnessed bleed. In our study the GUSTO classification was used, which defines major bleeding as intracerebral bleeding or bleeding resulting in hemodynamic compromise requiring treatment.¹³

Conclusions

The IHMB rate in our study was 1.8%. The CRUSADE score, although presenting some discriminatory power, significantly overestimated the IHMB rate, especially in patients at higher risk. These results question whether the CRUSADE score should continue to be used in the stratification of bleeding risk in ACS and whether specific measures should be taken on the basis of the score result.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

- Manzano-Fernández S, Sánchez-Martínez M, Flores-Blanco PJ, et al. Comparison of the global registry of acute coronary events risk score versus the can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines risk score to predict in-hospital mortality and major bleeding in acute coronary syndromes. *Am J Cardiol.* 2016;117:1047–54.
- Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. *Eur Heart J.* 2011;32:1854–64.
- Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. *Circulation.* 2011;123:2736–47.
- Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. *Circulation.* 2006;114:774–82.
- Rao SV, O'Grady K, Pieper KS, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. *Am J Cardiol.* 2005;96:1200–6.
- Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2014;64:e139–228.
- Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. *Circulation.* 2009;119:1873–82.
- Ariza-Solé A, Sánchez-Elvira G, Sánchez-Salado JC, et al. CRUSADE bleeding risk score validation for ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. *Thromb Res.* 2013;132:652–8.
- Abu-Assi E, Raposeiras-Roubin S, Lear P, et al. Comparing the predictive validity of three contemporary bleeding risk scores in acute coronary syndrome. *Eur Heart J Acute Cardiovasc Care.* 2012;1:222–3.

10. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). *Eur Heart J*. 2016;37:267–315.
11. Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. *Eur Heart J*. 2007;28:2525–38.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron*. 1976;16:31–41.
13. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. *N Engl J Med*. 1993;329:673–82.
14. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiology*. 1982;143:29–36.
15. Lemeshow S, Hosmer D. A review of goodness of fit statistic for use in the development of logistic regression models. *Am J Epidemiol*. 1982;115:92–106.
16. Fox K, Carruthers K, Steg G, et al. Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The Global Registry of Acute Coronary Events. *Eur Heart J*. 2010;31:667–75.
17. Spencer FA, Moscucci M, Granger CB, et al. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? *Circulation*. 2007;116:2793–801.
18. Ariza-Solé A, Salazar-Mendiguchía J, Lorente V, et al. Predictive ability of bleeding risk scores in the routine clinical practice. *Eur Heart J Acute Cardiovasc Care*. 2015;4:205–10.
19. Amador P, Santos JF, Gonçalves S, et al. Comparison of ischemic and bleeding risk scores in non-ST elevation acute coronary syndromes. *Acute Card Care*. 2011;13:68–75.
20. Faustino A, Mota P, Silva J, et al. Non-ST-elevation acute coronary syndromes in octogenarians: applicability of the GRACE and CRUSADE scores. *Rev Port Cardiol*. 2014;33:617–27.
21. Ariza-Solé A, Formiga F, Lorente V, et al. Efficacy of bleeding risk scores in elderly patients with acute coronary syndromes. *Rev Esp Cardiol*. 2014;67:463–70.
22. Mehran R, Pocock SJ, Nikolsky E, et al. A risk score to predict bleeding in patients with acute coronary syndromes. *J Am Coll Cardiol*. 2010;55:2556–66.
23. Moscucci M, Fox KA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). *Eur Heart J*. 2003;24:1815–23.
24. Nikolsky E, Mehran R, Dangas G, et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. *Eur Heart J*. 2007;28:1936–45.
25. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2009;361:1045–57.
26. Flores-Ríos X, Couto-Mallón D, Rodríguez-Garrido J, et al. Comparison of the performance of the CRUSADE, ACUITY-HORIZONS, and ACTION bleeding risk scores in STEMI undergoing primary PCI: insights from a cohort of 1391 patients. *Eur Heart J*. 2013;2:19–26.
27. Valgimigli M, Gagnor A, Calabró P, et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. *Lancet*. 2015;385:2465–76.
28. Vranckx P, Frigoli E, Rothenbühler M, et al. Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation. *Eur Heart J*. 2017;38:1069–80.
29. Feit F, Voeltz MD, Attubato MJ, et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. *Am J Cardiol*. 2007;100:1364.
30. Doyle BJ, Ting HH, Bell MR, et al. Major femoral bleeding complications after percutaneous coronary intervention: incidence, predictors, and impact on long-term survival among 17,901 patients treated at the Mayo Clinic from 1994 to 2005. *JACC Cardiovasc Interv*. 2008;1:202.
31. Chhatiwalla AK, Amin AP, Kennedy KF, et al. Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. *JAMA*. 2013;309:1022.
32. Sciahbasi A, Pristipino C, Ambrosio G, et al. Arterial access-site-related outcomes of patients undergoing invasive coronary procedures for acute coronary syndromes (from the Comparison of Early Invasive and Conservative Treatment in Patients With Non-ST-Elevation Acute Coronary Syndromes [PRESTO-ACS] Vascular Substudy). *Am J Cardiol*. 2009;103:796–800.
33. Romagnoli E, Biondi-Zoccai G, Sciahbasi A, et al. Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLESTEACS (Radial Versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome) study. *J Am Coll Cardiol*. 2012;60:2481–9.
34. Généreux P, Mehran R, Palmerini T, et al. Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial. *EuroIntervention*. 2011;7:905–16.
35. Jolly SS, Yusuf S, Cairns J, et al., RIVAL trial group. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. *Lancet*. 2011;377:1409–20.
36. Yusuf S, Mehta SR, Chrolavicius S, et al., Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. *N Engl J Med*. 2006;254:1464–76.
37. Correia LC, Ferreira F, Kalil F, et al. Comparison of ACUITY and CRUSADE scores in predicting major bleeding during acute coronary syndrome. *Arq Bras Cardiol*. 2015;105:20–7.
38. Boersma E, Akkerhuis KM, Theroux P, et al. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. *Circulation*. 1999;100:2045–8.
39. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. *N Engl J Med*. 2008;358:2218–30.

40. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J*. 2017, <http://dx.doi.org/10.1093/eurheartj/ehx393>.
41. Bellemain-Appaix A, Kerneis M, O'Connor SA, et al. Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis. *BMJ*. 2014;349, g6269.
42. Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. *N Engl J Med*. 2013;369:999–1010.